Upstream Bio, Inc. (UPB)
NASDAQ:UPB
Top Page
Upstream Bio, Inc.
(NASDAQ:UPB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$10.50
▼(-65.35% Downside)
Action:ReiteratedDate:03/27/26
The score is held back primarily by worsening losses and accelerating cash burn despite minimal revenue scale, and by weak longer-term technical trend signals. These are partly offset by a low-leverage, strengthened equity position and a supportive corporate catalyst from positive Phase 2 clinical results.
Positive Factors
Low leverage & strengthened equity
Very low debt and a materially improved equity base materially reduce solvency and refinancing risk. This durable balance-sheet strength gives management flexibility to fund multi-year clinical programs, negotiate partnerships, and avoid distressed financings while executing development plans.
Negative Factors
Accelerating cash burn & negative cash flow
Consistently negative operating and free cash flow with accelerating 2025 burn creates a persistent funding requirement. Over multiple quarters this reduces runway, forces prioritization of programs, and increases reliance on external capital which can delay timelines or alter development sequencing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage & strengthened equity
Very low debt and a materially improved equity base materially reduce solvency and refinancing risk. This durable balance-sheet strength gives management flexibility to fund multi-year clinical programs, negotiate partnerships, and avoid distressed financings while executing development plans.
Read all positive factors
Upstream Bio, Inc. (UPB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$570.87M
Dividend YieldN/A
Average Volume (3M)388.50K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.78
Shares Outstanding54,419,987
10 Day Avg. Volume473,530
30 Day Avg. Volume388,499
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue159.92
Enterprise Value/Gross Profit165.01
Enterprise Value/Ebitda-2.92
Forecast
1Y Price Target
$43.75Price Target Upside44.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.94
Revenue Forecast (FY)$1.41M
Upstream Bio, Inc. Business Overview & Revenue Model
Company Description
Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development ...
How the Company Makes Money
null...
Upstream Bio, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 2.85M | 2.37M | 2.38M | 1.21M |
| Gross Profit | 2.67M | 2.37M | 2.38M | 1.21M |
| EBITDA | -160.36M | -77.67M | -40.05M | -23.90M |
| Net Income | -143.44M | -62.81M | -20.54M | -23.87M |
Balance Sheet | ||||
| Total Assets | 353.77M | 481.72M | 117.20M | 18.48M |
| Cash, Cash Equivalents and Short-Term Investments | 341.51M | 470.45M | 109.81M | 17.05M |
| Total Debt | 1.27M | 1.83M | 45.00K | 94.00K |
| Total Liabilities | 14.00M | 11.87M | 240.32M | 124.63M |
| Stockholders Equity | 339.77M | 469.85M | -123.13M | -106.16M |
Cash Flow | ||||
| Free Cash Flow | -133.28M | -59.68M | -38.07M | -19.10M |
| Operating Cash Flow | -133.28M | -59.17M | -37.93M | -19.02M |
| Investing Cash Flow | -93.48M | -59.48M | -82.84M | -82.00K |
| Financing Cash Flow | 2.44M | 418.91M | 129.55M | 9.96M |
Upstream Bio, Inc. Technical Analysis
Neutral
30.30
Price Trends
12.52
Negative
20.53
Negative
18.99
Negative
Market Momentum
-0.46
Negative
52.54
Neutral
88.10
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPB, the sentiment is Neutral. The current price of 30.3 is above the 20-day moving average (MA) of 9.29, above the 50-day MA of 12.52, and above the 200-day MA of 18.99, indicating a neutral trend. The MACD of -0.46 indicates Negative momentum. The RSI at 52.54 is Neutral, neither overbought nor oversold. The STOCH value of 88.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UPB.
Upstream Bio, Inc. Risk Analysis
Upstream Bio, Inc. disclosed 80 risk factors in its most recent earnings report. Upstream Bio, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Upstream Bio, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $841.91M | 8.89 | 46.03% | ― | 27.12% | ― | |
62 Neutral | $1.38B | -6.67 | -32.49% | ― | ― | -103.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $570.87M | -10.19 | -36.48% | ― | ― | ― | |
50 Neutral | $619.29M | -2.57 | -178.61% | ― | 647.13% | 26.79% | |
50 Neutral | $1.17B | -1.76 | -156.98% | ― | ― | -38.04% | |
46 Neutral | $342.68M | -2.24 | -33.20% | ― | -23.43% | -9.84% |
* Healthcare Sector Average
UPB
Upstream Bio, Inc.
10.49
2.91
38.39%
TBPH
Theravance Biopharma
16.35
7.62
87.29%
BCYC
Bicycle Therapeutics
4.94
-2.13
-30.13%
PRME
Prime Medicine, Inc.
3.43
2.10
157.89%
BCAX
Bicara Therapeutics Inc.
21.12
9.74
85.59%
ZBIO
Zenas BioPharma, Inc.
20.44
11.94
140.47%
Upstream Bio, Inc. Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Upstream Bio Launches $150 Million At-The-Market Program
Neutral
Mar 26, 2026
On March 26, 2026, Upstream Bio, Inc. entered into a sales agreement with Leerink Partners LLC to establish an at-the-market equity program for its common stock. Under this arrangement, the company may, but is not obligated to, sell up to $150 mil...
Business Operations and StrategyProduct-Related Announcements
Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results
Positive
Feb 11, 2026
On February 11, 2026, Upstream Bio hosted a webcast to present top-line results from its Phase 2 VALIANT trial of verekitug in severe asthma, reporting that the study met its primary endpoint of reducing annualized asthma exacerbation rates. Verek...
Business Operations and StrategyProduct-Related Announcements
Upstream Bio Reports Positive Phase 2 Severe Asthma Data
Positive
Feb 11, 2026
On February 11, 2026, Upstream Bio reported positive top-line results from its Phase 2 VALIANT trial of verekitug in 478 adults with severe asthma, showing statistically significant and clinically meaningful reductions in annualized asthma exacerb...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.